-

04:08:41 AM

IFRX Stock News

IFRX - InflaRx N.V.

05/16/23 4:00 AM

OTC, Nasdaq : WXXWY, IFRX

partnershipcovid-19

WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients

WuXi Biologics, a leading global Contract Research, Development and Manufacturing Organization, announced the manufacturing partnership with InflaRx for its COVID-19 treatment Gohibic. InflaRx, a clinical-stage biopharmaceutical company headquartered in Jena, Germany developing anti-inflammatory therapeutics...

RHEA-AI

very positive

05/11/23 7:30 AM

Nasdaq : IFRX

earnings

InflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business Update

Emergency Use Authorization (EUA) granted by the U.S. Food and Drug Administration (FDA) for Gohibic (vilobelimab) for treatment of critically ill COVID-19 patients Gohibic planned to be available to patients in the U.S. within the next few weeks Phase III study with vilobelimab in pyoderma

RHEA-AI

neutral

04/18/23 4:01 PM

Nasdaq : IFRX

offering

InflaRx Announces Closing of the Full Exercise of Greenshoe Option Increasing the Proceeds of the Recently Announced Public Offering of Ordinary Shares to US$46 million

InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that, in connection with its previously announced completion of

RHEA-AI

neutral

04/14/23 4:01 PM

Nasdaq : IFRX

offering

InflaRx Announces Closing of $40 Million Public Offering of Ordinary Shares

InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that it has completed its underwritten public offering of

RHEA-AI

neutral

04/11/23 9:08 PM

Nasdaq : IFRX

offering

InflaRx Announces Pricing of $40 Million Public Offering of Ordinary Shares

InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today the pricing of its underwritten public offering of 9,411,765

RHEA-AI

neutral

04/11/23 4:00 PM

Nasdaq : IFRX

offering

InflaRx Announces Public Offering of Ordinary Shares

InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that it has commenced an underwritten public offering of ordinary

RHEA-AI

neutral

04/04/23 2:55 PM

Nasdaq : IFRX

covid-19

InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients

Vilobelimab is the first authorized drug to control complement factor C5a, a protein that plays an important and often harmful role in the body's immune response FDA granted EUA based on Phase III clinical trial results showing a significant relative reduction in 28-day all-cause mortality of 23.9%

RHEA-AI

positive

03/22/23 7:30 AM

Nasdaq : IFRX

InflaRx Reports Full Year 2022 Financial and Operating Results

Major progress in development of vilobelimab Phase III study in PG announced following detailed feedback and recommendations from the U.S. Food and Drug Administration (FDA); clinical trial protocol submitted; first patient expected around mid-2023 Fast Track and Orphan Drug designations granted

RHEA-AI

neutral

01/05/23 7:30 AM

Nasdaq : IFRX

covid-19

InflaRx Provides Update on Planned Phase III Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of its EUA Application in Critically Ill COVID-19 Patients

Multi-national, randomized, controlled adaptive Phase III design for vilobelimab in ulcerative pyoderma gangrenosum (PG) Trial size to be adapted upon interim analysis with planned total patient number between approximately 50 and 100 patients FDA review of application for emergency use

RHEA-AI

neutral

12/21/22 7:30 AM

Nasdaq : IFRX

covid-19

InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19

InflaRx will provide access to certain clinical, manufacturing and regulatory documentation for vilobelimab to facilitate STS’s regulatory filings in China STS plans to request regulatory approval in China for its own anti-C5a-antibody BDB-001 for the treatment of COVID-19 based on InflaRx’s

RHEA-AI

positive

1 2 3 4 5 6 7 Next

IFRX Data

IndustryPharmaceutical Preparation Manufacturing
Websiteinflarx.de
Security nameInflaRx N.V.
Issue typecs
SectorManufacturing
Sic code2834
Employees48
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
AddressWinzerlaer Str. 2
StateThueringen
CityJena
Zip07745
CountryGermany
Phone493641508180

About InflaRx N.V.

inflarx n.v., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using c5a technology primarily in the germany and united states. its c5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. the company's lead product candidate is ifx-1, an intravenously delivered first-in-class anti-c5a monoclonal antibody, which completed the phase iib clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat anca-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing ifx-1 for the treatment of oncological diseases. it also develops ifx-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. inflarx n.v. has co-development agreement with beijing defe